Phaseline

Companies › PMV Pharmaceuticals

PMV Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rezatapopt
p53 reactivator selective for TP53 Y220C mutation
TP53Phase 1Advanced Solid Tumor; TP53 Y220C Mutation; Myelodysplastic SyndromeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04585750rezatapoptPhase 1Advanced Solid TumorOncologyDec 2026
NCT07372625rezatapoptPhase 1TP53 Y220C MutationOncologyMar 2027
NCT06616636rezatapoptPhase 1Myelodysplastic SyndromeOncologyAug 2027

From the company's SEC filings

Cash and short-term investments of $109m on 2026-09-30; operating cash outflow about $70m a year; runway about 18 months at that burn, to Apr 2028

Press releases filed as 8-K in the last year:

Targets

TP53 (1)

Companies with the same targets

SynerGene Therapeutics Kartos Therapeutics Precigen OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Nutshell Therapeutics (Shanghai) Jacobio Pharmaceuticals Clasp Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.